IsoPlexis
IsoPlexis, now part of Bruker Cellular Analysis, develops single-cell functional proteomics instruments (IsoLight, IsoSpark) and consumables (Single-Cell Secretome, Single-Cell Signaling, CodePlex, Meteor) plus IsoSpeak software for pharma, biotech, and academic research labs studying immune response, antibody discovery, and cell therapy.
- Company typePrivate
- Founded2013
- HeadquartersBranford, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What IsoPlexis does
IsoPlexis is a life-science technology company that built a single-cell functional proteomics platform around its proprietary proteomic barcoding technology. Founded in 2013 and headquartered in Branford, Connecticut, the company developed benchtop instruments (IsoLight System, IsoSpark System) that capture highly multiplexed cytokine, chemokine, and phosphoprotein signatures from individual cells, paired with single-use chips (Single-Cell Secretome, Single-Cell Signaling, CodePlex: Walkaway Proteomics, Meteor: Quantitative Bulk Proteomics) and IsoSpeak software for data analysis and visualization. The technology is used to predict disease progression, treatment resistance, and therapeutic efficacy by linking functional proteomic readouts directly to single cells, with stated applications in therapeutic antibody discovery, cell and gene therapy, cancer immunology, and biomarker research.
The company sells high-value capital instruments, recurring consumables, and software licenses through direct enterprise field sales targeting pharmaceutical, biotechnology, and academic research customers. A Technology Access Program (TAP) provides an alternative, lower-friction entry point for labs to evaluate instruments without full capital purchase. Named customers and case-study users include Medical College of Wisconsin, Mycenax, and Abveris across academic and biotech segments. Cumulative disclosed private funding exceeded $200 million across rounds from 2014 to 2021, including an $85 million Series D led by Perceptive Advisors with Ally Bridge Group and BlackRock in January 2021.
IsoPlexis was acquired by Bruker and is now operated as part of Bruker Cellular Analysis, with the IsoLight, IsoSpark, and IsoSpeak lines marketed under the Proteomic Barcoding Suite. Post-acquisition, the product line is integrated with Bruker Spatial Biology's CosMx platform to combine live single-cell functional data with subcellular spatial imaging, and the Beacon optofluidic product family (Beacon Discovery, Beacon Quest, Beacon Select, Beacon Optofluidic System, Culture Station) has been brought into the same commercial organization. The company's original co-founder Rong Fan remains associated as a scientific advisor; current disclosed leadership includes John Strahley (CFO) and John Leamon (SVP R&D Integration).
IsoPlexis firmographics
Firmographics- Name
- IsoPlexis
- Website
- https://isoplexis.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- IsoPlexis, now part of Bruker Cellular Analysis, develops single-cell functional proteomics instruments (IsoLight, IsoSpark) and consumables (Single-Cell Secretome, Single-Cell Signaling, CodePlex, Meteor) plus IsoSpeak software for pharma, biotech, and academic research labs studying immune response, antibody discovery, and cell therapy.
- Ownership category
- akta.pro rank
IsoPlexis industry classification
Industry- Product category
- Single-Cell Proteomics Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Proteomics & Biomarker Analytical Testing (HLAGADAG)
- akta.pro secondary industries
- Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Translational Medicine & Biomarkers (HLAIALAF), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where IsoPlexis is headquartered
LocationHeadquarters
- HQ city
- Branford
- HQ country
- United States
- HQ region
- North America
Markets served
IsoPlexis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Revenue model
- Instrument Sales: Sale of capital equipment including IsoLight and IsoSpark systems for single-cell proteomics analysis. These are high-value instruments sold to pharma, biotech, and academic research labs.
- Consumables/Kits: Single-use chips and reagents including Single-Cell Secretome and Single-Cell Signaling chips that are consumed with each run.
- Software Licenses: IsoSpeak software for data analysis, likely sold as subscriptions or licenses for ongoing access to updates and support.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
IsoPlexis product offering
Product offeringCore offering
IsoPlexis (now part of Bruker Cellular Analysis) develops and sells the Proteomic Barcoding Suite, which includes the IsoLight and IsoSpark benchtop instruments that capture highly multiplexed cytokine, chemokine, and phosphoprotein signatures from single cells, paired with single-use chip consumables (Single-Cell Secretome, Single-Cell Signaling, CodePlex, Meteor) and the IsoSpeak data analysis software. The platform enables researchers in pharma, biotech, and academic labs to predict disease progression, treatment resistance, and therapeutic efficacy by linking functional readouts directly to individual cells.
Product overview
IsoPlexis, now part of Bruker Cellular Analysis, offers the Proteomic Barcoding Suite—a platform of instruments, chips, and software for single-cell and bulk proteomics analysis. The core instruments include the IsoLight System and IsoSpark System for capturing multiplexed cytokine, chemokine, and phosphoprotein signatures from single cells. These are complemented by chip products (Single-Cell Secretome, Single-Cell Signaling, CodePlex: Walkaway Proteomics, Meteor: Quantitative Bulk Proteomics) and the IsoSpeak Software for data analysis and visualization. The suite enables researchers to predict disease progression, treatment resistance, and therapeutic efficacy through comprehensive proteomics profiling.
Differentiator
Problem solved
Functional benefit
Brands
- IsoLight System: Single-cell proteomics system for proteomic barcoding workflow
- IsoSpark System
- IsoSpeak Software
Products and services
- IsoLight System
Companies that use IsoPlexis
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
IsoPlexis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
IsoPlexis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CosMx (Bruker Spatial Biology)coreIntegration between Beacon platforms and CosMx Spatial Molecular Imager enables linking live T cell function data with spatial biology insights. The combined solution provides single-cell functional data from Beacon instruments paired with subcellular resolution spatial imaging and true spatial context from CosMx on the same cells.
Recent moves6 records
Expansion highlights6 records
IsoPlexis competitors and assessment
Company assessmentDirect peers
- 10x Genomics: 10x Genomics offers Chromium single-cell instruments and assays spanning genomics, transcriptomics, and multi-omics. It is the dominant incumbent in single-cell analysis and directly competes with IsoPlexis for cell therapy, immunology, and translational research workflows where researchers choose between platforms.
- Berkeley Lights (now PhenomeX): PhenomeX (formerly Berkeley Lights) sells optofluidic Beacon instruments for live single-cell functional screening in antibody discovery and cell line development. It is the most direct technology peer to IsoPlexis's optofluidic and functional proteomics offering and is explicitly highlighted on the Bruker Cellular Analysis website as adjacent technology.
- Standard BioTools (formerly Fluidigm): Standard BioTools manufactures the Hyperion imaging mass cytometry and CyTOF/Helios platforms for highly multiplexed single-cell protein profiling. It competes head-to-head with IsoPlexis on deep single-cell proteomic readouts for immunology and translational research customers.
- Mission Bio: Mission Bio's Tapestri platform performs single-cell multi-omics (DNA + protein) for clonal profiling in oncology and cell therapy. It targets overlapping translational and cell therapy customer segments where IsoPlexis sells its polyfunctional profiling workflows.
- Cytek Biosciences: Cytek sells Aurora and Northern Lights spectral flow cytometers used for high-parameter immune cell phenotyping. It competes with IsoPlexis for immunology and cell therapy customers seeking deep single-cell protein readouts, particularly where flow cytometry remains the workflow of choice.
Emerging players
- Parse Biosciences: Parse Biosciences offers scalable single-cell sequencing kits (Evercode) without dedicated instrumentation. While focused on transcriptomics rather than proteomics, it competes for single-cell project budgets in academic and translational labs that might otherwise purchase IsoPlexis instruments.
- Olink Holding (part of Thermo Fisher): Olink's proximity extension assay technology delivers highly multiplexed protein biomarker measurements from small samples. Recently acquired by Thermo Fisher, it competes for translational proteomics budgets and biomarker discovery projects that IsoPlexis targets in pharma and academic settings.
Broad incumbents
- BD Biosciences (Becton Dickinson): BD Biosciences offers the FACSDiscover S8 and BD CellView image-enabled cell sorters plus a broad flow cytometry portfolio. As a major life sciences incumbent with global reach, it is a default alternative for cell therapy and immunology customers evaluating IsoPlexis instruments.
- Bio-Techne: Bio-Techne provides a broad portfolio of life science reagents, proteins, and analytical tools including single-cell proteomics reagents (e.g., RNAscope, proteome profiler arrays). It is a broad incumbent that overlaps with IsoPlexis at the consumables and assay level rather than at the instrument level.
- NanoString Technologies: NanoString (now operating under Bruker ownership of its spatial biology assets) developed the CosMx and GeoMx spatial biology platforms that IsoPlexis integrates with via its CosMx partnership. It is adjacent rather than directly competitive and serves overlapping translational research customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
IsoPlexis social profiles
Digital presenceIsoPlexis financial estimates
Financial estimateRevenue estimate
Valuation estimate
IsoPlexis leadership team
Management profileNumber of profiles
Profiles5 records
IsoPlexis funding detail
Funding detailFunding overview
Funding rounds11 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IsoPlexis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IsoPlexis
What does IsoPlexis do?
IsoPlexis (now part of Bruker Cellular Analysis) develops and sells the Proteomic Barcoding Suite, which includes the IsoLight and IsoSpark benchtop instruments that capture highly multiplexed cytokine, chemokine, and phosphoprotein signatures from single cells, paired with single-use chip consumables (Single-Cell Secretome, Single-Cell Signaling, CodePlex, Meteor) and the IsoSpeak data analysis software. The platform enables researchers in pharma, biotech, and academic labs to predict disease progression, treatment resistance, and therapeutic efficacy by linking functional readouts directly to individual cells.
Is IsoPlexis a public or private company?
IsoPlexis is a private company. It is classified as corporate owned and is currently acquired.
When was IsoPlexis founded?
IsoPlexis was founded in 2013. It employs 101 to 250 people.
Where is IsoPlexis based?
IsoPlexis is headquartered in Branford, United States, in the North America region.
How does IsoPlexis make money?
Three revenue lines are on record. Instrument Sales are the primary driver. The others are consumables/Kits and software Licenses.
Who are IsoPlexis's main competitors?
Direct peers on record are 10x Genomics, Berkeley Lights (now PhenomeX), Standard BioTools (formerly Fluidigm), Mission Bio and Cytek Biosciences. Emerging players are Parse Biosciences and Olink Holding (part of Thermo Fisher). Broad incumbents are BD Biosciences (Becton Dickinson), Bio-Techne and NanoString Technologies.
Does IsoPlexis have an API?
No public API is recorded for IsoPlexis.
What industry is IsoPlexis in?
IsoPlexis's product category is Single-Cell Proteomics Instruments. Its primary akta.pro industry code is HLAGADAG, Proteomics & Biomarker Analytical Testing, with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 334516 and its SIC code is 3826.